quarfloxin
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00955786)
Timeline
Indications
Mechanism of action
- NucleolinBLOCKER
NCL blocker
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCC[C@H]1CCNC(=O)c1cn2c3c(c(N4CCC(c5cnccn5)C4)c(F)cc3c1=O)Oc1cc3ccccc3cc1-2- Mol. weight
- 604.69 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989407 ↗
- ChEMBLCHEMBL2103818 ↗
Also known as
- cx3543
- cx 3543
- cx-3543
- cx-3543
- cx-3543
- cx-3543
- quarfloxin
- quarfloxin
- quarfloxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00780663 | Phase 2 | Oct 1, 2008 | Cylene Pharmaceuticals |
| NCT00955292 | Phase 1 | Jul 1, 2007 | Cylene Pharmaceuticals |
| NCT00485966 | Phase 2 | Jun 1, 2007 | Cylene Pharmaceuticals |
| NCT00955786 | Phase 1 | Jul 1, 2005 | Cylene Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cylene Pharmaceuticals | For profit | 4 | 4 | 2 | 2005 |
1 organizations
Page 1 / 1